NCT01025934已完成4 期
Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
研究概览
简要总结
The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •vitreous haemorrhage
- •tractional retinal detachment
- •active proliferative diabetic retinopathy.
排除标准
- •neovascular glaucoma
- •combined traction and rhegmatogenous RD
研究组 & 干预措施
7 days
Active Comparator
干预措施: Bevacizumab (Drug)
20 days
Active Comparator
干预措施: Bevacizumab (Drug)
sham
Sham Comparator
干预措施: sham (Other)
研究者
相似试验
Unknown
2 期
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of PrematurityRetinopathy of PrematurityNCT00622726The University of Texas Health Science Center, Houston150
已完成
3 期
Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic RetinopathyTractional Retinal Detachment Secondary to Proliferative Diabetic RetinopathyNCT01976923J. Fernando Arevalo, MD FACS224
已完成
3 期
Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)Age Related Macular DegenerationNCT01327222IRCCS San Raffaele20
Unknown
不适用
Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.NCT01707745Sivakami A Pai50
已完成
1 期
Preoperative Bevacizumab for Vitreous HemorrhageVitreous HemorrhageDiabetic RetinopathyNCT00596297University of Sao Paulo16